Literature DB >> 34273035

RNA-sequencing identification and validation of genes differentially expressed in high-risk adenoma, advanced colorectal cancer, and normal controls.

Namjoo Kim1, Jeong-An Gim2, Beom Jae Lee3, Byung Il Choi1, Seung Bin Park1, Hee Sook Yoon1, Sang Hee Kang4, Seung Han Kim1, Moon Kyung Joo1, Jong-Jae Park1, Chungyeul Kim5, Han-Kyeom Kim5.   

Abstract

Distinct gene expression patterns that occur during the adenoma-carcinoma sequence need to be determined to analyze the underlying mechanism in each step of colorectal cancer progression. Elucidation of biomarkers for colorectal polyps that harbor malignancy potential is important for prevention of colorectal cancer. Here, we use RNA sequencing to determine gene expression profile in patients with high-risk adenoma treated with endoscopic submucosal dissection by comparing with gene expression in patients with advanced colorectal cancer and normal controls. We collected 70 samples, which consisted of 27 colorectal polyps, 24 cancer tissues, and 19 normal colorectal mucosa. RNA sequencing was performed on an Illumina platform to select differentially expressed genes (DEGs) between colorectal polyps and cancer, polyps and controls, and cancer and normal controls. The Kyoto Gene and Genome Encyclopedia (KEGG) and gene ontology (GO) analysis, gene-concept network, GSEA, and a decision tree were used to evaluate the DEGs. We selected the most highly expressed genes in high-risk polyps and validated their expression using real-time PCR and immunohistochemistry. Compared to patients with colorectal cancer, 82 upregulated and 24 downregulated genes were detected in high-risk adenoma. In comparison with normal controls, 33 upregulated and 79 downregulated genes were found in high-risk adenoma. In total, six genes were retrieved as the highest and second highest expressed in advanced polyps and cancers among the three groups. Among the six genes, ANAX3 and CD44 expression in real-time PCR for validation was in good accordance with RNA sequencing. We identified differential expression of mRNAs among high-risk adenoma, advanced colorectal cancer, and normal controls, including that of CD44 and ANXA3, suggesting that this cluster of genes as a marker of high-risk colorectal adenoma.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  ANAX3; Advanced colorectal cancer; CD44; High risk adenoma; Precision medicine; RNA sequencing

Mesh:

Substances:

Year:  2021        PMID: 34273035     DOI: 10.1007/s10142-021-00795-8

Source DB:  PubMed          Journal:  Funct Integr Genomics        ISSN: 1438-793X            Impact factor:   3.410


  43 in total

1.  Change in annexin A3 expression by regulatory factors of hepatocyte growth in primary cultured rat hepatocytes.

Authors:  Mizuho Harashima; Shingo Niimi; Hitomi Koyanagi; Masashi Hyuga; Seiji Noma; Taiichiro Seki; Toyohiko Ariga; Toru Kawanishi; Takao Hayakawa
Journal:  Biol Pharm Bull       Date:  2006-07       Impact factor: 2.233

2.  Molecular characterization of "sessile serrated" adenoma to carcinoma transition in six early colorectal cancers.

Authors:  Rocco Cappellesso; Marcello Lo Mele; Giada Munari; Erik Rosa-Rizzotto; Ennio Guido; Franca De Lazzari; Pierluigi Pilati; Marco Tonello; Fabio Farinati; Stefano Realdon; Matteo Fassan; Massimo Rugge
Journal:  Pathol Res Pract       Date:  2019-02-03       Impact factor: 3.250

3.  Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.

Authors:  Feifeng Jing; Hun Jin Kim; Chang Hyun Kim; Young Jin Kim; Jae Hyuk Lee; Hyeong Rok Kim
Journal:  Int J Oncol       Date:  2015-01-23       Impact factor: 5.650

4.  Inhibition of experimental tumours by defibrinogenation.

Authors:  J P Austin; E M Glaser
Journal:  Clin Sci       Date:  1969-12       Impact factor: 6.124

Review 5.  Colorectal endoscopic submucosal dissection (ESD).

Authors:  Lorenzo Fuccio; Thierry Ponchon
Journal:  Best Pract Res Clin Gastroenterol       Date:  2017-07-06       Impact factor: 3.043

6.  The MiR-495/Annexin A3/P53 Axis Inhibits the Invasion and EMT of Colorectal Cancer Cells.

Authors:  Zhigang Bai; Jin Wang; Tingting Wang; Yuan Li; Xiaomu Zhao; Guocong Wu; Yingchi Yang; Wei Deng; Zhongtao Zhang
Journal:  Cell Physiol Biochem       Date:  2017-12-08

7.  Global patterns and trends in colorectal cancer incidence and mortality.

Authors:  Melina Arnold; Mónica S Sierra; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  Gut       Date:  2016-01-27       Impact factor: 23.059

8.  Identification of prognostic biomarkers in colorectal cancer using a long non-coding RNA-mediated competitive endogenous RNA network.

Authors:  Minjie He; Yan Lin; Yuzhen Xu
Journal:  Oncol Lett       Date:  2019-01-15       Impact factor: 2.967

Review 9.  Colorectal Cancer Screening-Who, How, and When?

Authors:  Roisin Bevan; Matthew D Rutter
Journal:  Clin Endosc       Date:  2018-01-31

Review 10.  Should We Resect and Discard Low Risk Diminutive Colon Polyps.

Authors:  Pujan Kandel; Michael B Wallace
Journal:  Clin Endosc       Date:  2019-01-21
View more
  2 in total

1.  In silico identification of novel biomarkers for key players in transition from normal colon tissue to adenomatous polyps.

Authors:  Zerrin Isik; Asım Leblebici; Ezgi Demir Karaman; Caner Karaca; Hulya Ellidokuz; Altug Koc; Ender Berat Ellidokuz; Yasemin Basbinar
Journal:  PLoS One       Date:  2022-04-29       Impact factor: 3.752

2.  Crosstalk between mucosal microbiota, host gene expression, and sociomedical factors in the progression of colorectal cancer.

Authors:  Namjoo Kim; Jeong-An Gim; Beom Jae Lee; Byung Il Choi; Hee Sook Yoon; Seung Han Kim; Moon Kyung Joo; Jong-Jae Park; Chungyeul Kim
Journal:  Sci Rep       Date:  2022-08-04       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.